Intercell AG

Single-cell commercial leader Simone Günther, US biotech veteran Sandy Zweifach, and Werner Lanthaler (Wlanholding) join to guide Myllia's next phase of growth Vienna, Austria – October 8, 2026 – Myllia Biotechnology, a specialist in high-content CRISPR screens in primary human cells, today announced the formation of its Board. The new governance body will oversee and advise Myllia's management team, led by co-founders Dr. Thomas Moser (CEO) and Dr. Tilmann Buerckstuemmer (CSO). The Board comprises Sandy Zweifach as Chair, Dr. Simone Günther, and Dr. Werner Lanthaler The Board is formed at a time of strong momentum for Myllia. Building on its single-cell CRISPR screening platform (Perturb-seq), the company has launched VISTA™, the first platform for genome-wide CRISPR screens in primary human cells, and has added multimodal optical pooled screening to its offering. At the same time, demand is rising for large, human-relevant perturbation datasets to train AI models of cell biology – an area where Myllia's primary-cell data are increasingly sought after by pharma and biotech partners. About the Board members Dr. Simone Günther brings more than 20 years of commercial leadership in life science tools and molecular diagnostics companies across Europe, the Middle East and Africa. Most recently, she led the Single-Cell MultiOmics business in EMEA at BD Biosciences (now part of Waters), with full P&L responsibility for the BD Rhapsody™ portfolio. At BD, she built the European single-cell multiomics commercial team from the ground up and later led the EMEA Scientific & Application Support organization of more than 90 people. Earlier roles include Business & Medical Lead for Molecular Diagnostics at QIAGEN and Director Market Development & Business Strategy at Thermo Fisher Scientific (Life Technologies). Simone holds a PhD in Biology from the University of Karlsruhe and completed a postdoctoral fellowship at Yale University. Sandy Zweifach has more than 35 years of experience in the life sciences industry, with deep relationships across pharma R&D, business development and the investment community. He has served as CEO or President of five companies, raised more than $750 million in capital and led numerous M&A and licensing transactions. Most recently, he led Imidomics, Inc. as their CEO and successfully sold the core business to UCB. Sandy is a Senior Advisor to Bioqube Ventures and holds several board positions, including Executive Chair of Paradox Immunotherapeutics and non-executive director of Compugen. He holds an MS in Human Physiology from the University of California, Davis, and a BA in Biology from the University of California, San Diego. Dr. Werner Lanthaler served as CEO of Evotec SE from 2009 to 2024. Before Evotec, he was CFO of Intercell AG, where he led Austria's first VC-backed biotech IPO, and earlier worked with McKinsey & Company. Werner is CEO of FairJourney Biologics and founder of WLan Holding, a Vienna-based investment company focused on life sciences and sustainability. He serves on several boards, including InSphero, HAL Allergy, Proxygen, Elucidata. He holds a PhD in Business Administration from WU Vienna and a Master of Public Administration from Harvard University. Quotes “With Simone, Sandy, and Werner, we gain a Board that combines exactly the experience we need for our next stage: building a global discovery business, commercializing cutting-edge single-cell technology, and partnering with pharma in the US and Europe," said Dr. Thomas Moser, CEO and co-founder of Myllia Biotechnology . "We look forward to their guidance as we scale our platform and our partnerships." "Functional genomics in primary human cells and the data Myllia generates are extremely value inputs for AI-driven drug discovery,” said Sandy Zweifach . "I am delighted to support a Vienna-based team that has built a truly differentiated platform." About Myllia Biotechnology Myllia Biotechnology is a Vienna-based company that combines CRISPR perturbation screens with single-cell and image-based readouts in primary human cells to deliver mechanistic, human-relevant insights for drug discovery. Its end-to-end platform supports CRISPR knockout, interference and activation screens in immune, metabolic, renal and cancer cell models, enabling target discovery, mode-of-action studies and the generation of AI-ready perturbation datasets. Myllia partners with pharmaceutical and biotech companies worldwide. For more information, visit myllia.com . Media contact Tilmann Buerckstuemmer Email tb@myllia.com Phone +4369911431964 Myllia Biotechnology GmbH Am Kanal 27 1110 Wien Austria Photos From left to right: Sandy Zweifach, Simone Günther, Werner Lanthaler

PORTO, Portugal--(BUSINESS WIRE)--FairJourney Biologics S.A., global leader in antibody discovery and development, today announced the formation of its Supervisory Board to support the Company’s ongoing strategy for growth and innovation. Comprising experienced biotech leaders with proven track records for success, the strategic initiative will focus on driving cutting-edge research, reinforcing the Company’s commitment to excellence in antibody research and to accelerate innovation in the field. The newly formed board will be chaired by Dr. Werner Lanthaler, a renowned voice in the industry with an extensive career driving biopharmaceutical innovation. Dr. Lanthaler is currently CEO of the investment firm Wlanholding, and brings significant experience leading strategic growth initiatives, having held several executive-level roles including CEO of Evotec AG and CFO at Intercell AG. Throughout his career, Dr. Lanthaler helped to drive commercial success and long-term growth, including leading several collaborative partnerships with global pharmaceutical, biotechnology, and academic institutions. Dr. Lanthaler holds a Ph.D. in Economics from the University of Vienna and a master’s degree in public administration from Harvard University’s Kennedy School of Government. Joining Lanthaler on the board is Dr. Mikael Dolsten, widely recognized for his contributions to leading pharmaceutical companies and leadership in the global healthcare sector. Dr. Dolsten brings over 25 years’ experience leading cross-functional research and development programs and advancing innovative therapeutic solutions across diverse organizations, including as Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer. Several of the initiatives led by his teams have resulted in new treatment options that have helped to significantly improve patient care worldwide. He holds both a M.D., Ph.D. and a Professorship in Medicine (Visiting) from Lund University in Sweden. The board also welcomes Dr. Tariq Ghayur, an accomplished expert with over 30 years’ experience in biologics early discovery, development of bi- and multi-specific biologics platforms and translational medicine. Having previously held senior leadership positions at BASF Pharma, Abbott Laboratories, and most recently as Distinguished Research Fellow and Head of Foundational Immunology Department at AbbVie, Dr. Ghayur is widely experienced in leading multi-disciplinary, cross-therapeutic area Biologics discovery programs and developing novel biologics platforms, several of which have resulted in clinical development candidates. He holds a Ph.D. in Immunology from McGill University and completed his post-doctoral training at Dana Farber Cancer Institute. Partners Group, one of the largest firms in the global private markets industry, which invested in a majority stake in FairJourney Biologics in 2024 on behalf of its clients, will be represented on the Supervisory Board through the appointment of Dr. Remy Hauser and Pascal Noth. GHO Capital, the European specialist investor in global healthcare, which owns a minority stake in FairJourney Biologics, will be represented through Edward de Nor. Dr. Werner Lanthaler, Supervisory Board Chair, FairJourney Biologics, commented: “I am honored to join the Supervisory Board at such a pivotal time. My goal is to foster an environment of rigorous scientific and agile decision-making that will help to further development of Fairjourney Biologics’ breakthrough antibody solutions. I look forward to leveraging my background in pharmaceutical strategy and regulatory excellence to guide our company toward new achievements and continue to cement its position as the strategic partner of choice for the antibody community.” António Parada, CEO, FairJourney Biologics, said: “Our new board marks an exciting chapter for FairJourney Biologics. With leaders of such exceptional caliber and diverse backgrounds joining us, we are well-positioned to drive innovation and excellence in the antibody space. Their collective expertise and strategic vision will be instrumental in elevating our service offerings in the global market.” Dr. Tariq Ghayur, Supervisory Board Member, FairJourney Biologics noted: “In today’s dynamic biomedical landscape, the speedy development of innovative biologics and associated technologies is key. I am eager to work with my fellow board members to ensure that our innovation not only advances scientific knowledge but also translates into tangible benefits for patients worldwide” Dr. Mikael Dolsten, Supervisory Board Member, FairJourney Biologics, added: “The formation of this Board represents a unique opportunity to bridge cutting-edge research with real-world application. We're excited to redefine the interplay between outsourcing and strategic partnering, forging stronger collaborations to drive innovation and deliver transformative solutions." For more information, please visit: https://fjbio.com/

SCHLIEREN, Switzerland--(BUSINESS WIRE)-- LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors. Mr. Leavenworth Bakali brings over 30 years of senior executive and board-level experience in the life science and healthcare industries. He has led early-stage and mature companies through product development, growth, and commercialization while raising significant capital and has been closely involved in several successful exits. He succeeds Dr. Philippe Dro, who will remain a member of the Board of Directors representing Adjuvant Capital. "Staph is an exceptional leader, knowing what it takes to transform vaccine candidates into commercial products, and we will greatly benefit from his deep global experience as we advance our pipeline towards the next key milestones," said Dr. Franz-Werner Haas, CEO of LimmaTech. "His background in commercial and impact-driven enterprises, familiarity with high and low to middle-income countries, and roles in large and small companies brings valuable expertise to LimmaTech's mission to address the global threat of antimicrobial resistance while generating value for our stakeholders. I would like to thank Philippe for his dedication and guidance as Chair since the genesis of LimmaTech and am delighted that he will continue contributing to LimmaTech on the Board." Staph Leavenworth Bakali added, "As antimicrobial resistance continues to rise globally, infections will become increasingly difficult or impossible to treat. LimmaTech is at the forefront of combating this epidemic with a robust pipeline of vaccine candidates that can mitigate this escalating risk and control several highly transmissible pathogens. I look forward to sharing my experience and working with the LimmaTech team in our mission to address significant global medical needs and making a meaningful impact on people’s lives." Mr. Leavenworth Bakali most recently served as Chief Executive Officer (CEO) and President of George Health Enterprises, the commercial arm of The George Institute for Global Health, a leading medical research institute. In this role, he was deeply involved in establishing and growing a portfolio of companies focused on providing market-disruptive treatments, technologies, devices, and services addressing the large and fast-growing global chronic disease market. Previously, he served as President and Chief Operating Officer at the Clinton Health Access Initiative (CHAI), a non-profit organization founded by former U.S. President Bill Clinton. Mr. Leavenworth Bakali held several senior leadership roles in the vaccine industry, including CEO and Director of vaccine development companies Genocea Biosciences and Intercell, respectively. He served as Chief Operating Officer at ID Biomedical and PowderJect Pharmaceuticals, which were acquired by GlaxoSmithKline and Chiron, respectively. He served as the Global Commercial Head of Sales for Chiron’s global vaccine business and the Director of SmithKline Beecham’s vaccine business unit in France. Mr. Leavenworth Bakali holds a Masters in Management from the London Business School. About LimmaTech Biologics LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide. LimmaTech Biologics is backed by specialist healthcare investors, including Adjuvant Capital, AXA IM Alts, Novo Holdings REPAIR Impact Fund, and Tenmile. For more information, please visit . View source version on businesswire.com: Contacts LimmaTech Biologics AG Franz-Werner Haas, CEO E-Mail: media@lmtbio.com For media enquiries Sara Ortiz or Jacob Verghese Trophic Communications Phone: +49 151 7441 6179 Email: limmatech@trophic.eu Source: LimmaTech Biologics AG View this news release online at: